Changhong Li

Changhong Li has extensive work experience in the biopharmaceutical and research sectors. Changhong is currently serving as the Chief Scientific Officer at Hua Medicine's subsidiary, Nanjing AscendRare Pharmaceutical Technology Co., Ltd. This company focuses on developing innovative medicines to treat metabolic diseases, including orphan diseases.

Prior to their current role, Li was the Founder and CEO of Nanjing AscendRare Pharmaceutical Technology Co., where they utilized their leadership skills to establish and manage the company.

Changhong also worked as an Associate Director at the Nanjing Institute of Advanced Biotechnology and Life Science from October 2018 to April 2021. During this time, they played a key role in directing and supporting advanced biotechnology research projects.

Before joining Nanjing AscendRare Pharmaceutical Technology Co. and the Nanjing Institute of Advanced Biotechnology and Life Science, Li had an extensive tenure at the Children's Hospital of Philadelphia. Changhong served as a Research Assistant Professor from January 2010 to September 2018 and as a Scientist from May 2003 to December 2009. During their time at the hospital, they made significant contributions to various research projects.

Li began their research career as a Postdoctoral Fellow at the Children's Hospital of Philadelphia @ University of Pennsylvania from June 2000 to April 2003.

Overall, Changhong Li's work experience showcases their expertise in the biopharmaceutical and research fields, with a focus on metabolic diseases and orphan diseases.

Changhong Li attended Beijing Medical University from 1991 to 1996. Changhong earned a bachelor's degree in medicine during their time there.